WHO produced guidelines dealing with hepatitis C treatment
, 27 April, 2016 18:03
These guidelines serve as a framework that can allow the expansion of clinical services to patients with HCV infection.
These are the first guidelines dealing with hepatitis C treatment produced by the World Health Organization (WHO) and complement existing guidance on the prevention of transmission of bloodborne viruses, including HCV.
They are intended for policy-makers, government officials, and others working in low- and middleincome countries who are developing programmes for the screening, care and treatment of persons with HCV infection.
These guidelines serve as a framework that can allow the expansion of clinical services to patients with HCV infection, as they provide key recommendations in these areas and discuss considerations for implementation. The guidelines are also intended for health-care providers who care for persons with HCV infection in low- and middle-countries and provide them guidance in the management of patients infected with HCV.
Appendices
Appendix 1
- PICO questions for the WHO Hepatitis C Treatment Guidelines Evidence Reviews
(file size: 468 Kb)
Appendix 2
- GRADE template
(file size: 334 Kb)
Appendix 3 - Evidence summaries
- PICO 1: Testing - A systematic review and meta-‐analysis of targeted HCV antibody testing interventions
(file size: 923 Kb) - PICO 2: Screening - A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy
(file size: 515 Kb) - PICO 3: Care - A systematic review of interventions to reduce alcohol consumption among individuals with chronic HCV infection
(file size: 673 Kb) - PICO 4 Staging - Effectiveness of non-invasive fibrosis testing in CHC
(file size: 2.1 MB) - PICO 5: Treatment - A systematic review of the effectiveness of antiviral treatment compared with no treatment for chronic HCV infection
(file size: 968 Kb) - PICO 6: Treatment - Pegylated interferon plus ribavirin versus standard interferon plus ribavirin for chronic hepatitis C infection: a meta-analytical systematic review
(file size: 1 MB) - PICO 7: Treatment - Direct acting antiviral therapy versus pegylated interferon and ribavirin treatment for chronic hepatitis C infection: a meta-analytical systematic review
(file size: 682 Kb) - PICO 7: Treatment - Second Generation Direct Acting Antivirals for chronic Hepatitis C: sofosbuvir and simeprevir – a systematic review and meta-analysis using GRADE
(file size: 1 MB)
Appendix 4 - Decision making tables
- PICO 1 Testing - Antibody testing
(file size: 453 Kb) - PICO 2 Testing - RNA testing
(file size: 378 Kb) - PICO 3 Care - Behavioural interventions and alcohol consumption
(file size: 432 Kb) - PICO 4 Care - Fibrosis
(file size: 542 Kb) - PICO 5 Treatment - Interferon vs placebo
(file size: 569 Kb) - PICO 6 Treatment - PEG-interferon vs interferon
(file size: 558 Kb) - PICO 7 Treatment - Pegylated interferon and ribavirin vs. DAAs
(file size: 577 Kb) - PICO 7 Treatment - Simeprevir
(file size: 447 Kb) - PICO 7 Treatment - Sofosbuvir
(file size: 577 Kb)
Appendix 5
- WHO technical report on monitoring timepoints in adult patients treated for HCV with Pegylated interferon alpha and ribavirin
(file size: 1.49 MB)
Appendix 6
- Summary of declared interests of members of Guidelines Development Group
(file size: 284 Kb)
Related links
Файлы
